A pre-emptive approach to treating leukaemia relapse : compa

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is helping patients live longer with acute myeloid leukaemia (AML).

Related Keywords

Melbourne , Victoria , Australia , Nemes Laszlo , Peter Mac , Andrew Wei , Lymphoma Group , Peter Maccallum Cancer Centre Mac , Peter Maccallum Cancer Centre , Ing Soo Tiong , Clinical Oncology , Royal Melbourne Hospital , Australasian Leukaemia , Leukaemia , Relapse , Measurable Residual Disease , Yard , Chemotherapy , Acute Myeloid Leukaemia , Pml , Journal Of Clinical Oncology ,